They are classified as glucagon-like peptide 1 (GLP-1) agonists and, in addition to diabetes treatment, also demonstrate other benefits including weight loss and protective heart-health effects.While ...

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist tirzepat ...

Trulicity is another type of GLP-1 receptor agonist that is effective for reducing blood sugar levels and heart disease risk in people with diabetes. Like Ozempic, it’s an injectable medication ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The company is also known for drugs to treat diabetes (Trulicity, Humalog) and depression (Prozac, Cymbalta).

TUESDAY, Feb. 11, 2025 (HealthDay News) -- Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease ...